Literature DB >> 19205759

Chemical function-based pharmacophore generation of selective kappa-opioid receptor agonists by catalyst and phase.

Jing Zhang1, Guixia Liu, Yun Tang.   

Abstract

Two chemical function-based pharmacophore models of selective kappa-opioid receptor agonists were generated by using two different programs: Catalyst/HypoGen and Phase. The best output hypothesis (Hypo1) of HypoGen consisted of five features: one hydrogen-bond acceptor (HA), three hydrophobic points (HY), and one positive ionizable function (PI). The highest scoring model (Hypo2) produced by Phase comprised four features: one acceptor (A), one positive ionizable function (P), and two aromatic ring features (R). These two models (Hypo1 and Hypo2) were then validated by test set prediction and enrichment factors. They were shown to be able to identify highly potent kappa-agonists within a certain range, and satisfactory enrichments were achieved. The features of these two pharmacophore models were similar and consistent with experiment data. The models produced here were also generally in accord with other reported models. Therefore, our pharmacophore models were considered as valuable tools for 3D virtual screening, and could be useful for designing novel kappa-agonists.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19205759     DOI: 10.1007/s00894-008-0418-5

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  33 in total

1.  Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.

Authors:  Eva M Krovat; Thierry Langer
Journal:  J Med Chem       Date:  2003-02-27       Impact factor: 7.446

2.  Dissecting G-protein-coupled receptors: structure, function, and ligand interaction.

Authors:  Harald Schwalbe; Günther Wess
Journal:  Chembiochem       Date:  2002-10-04       Impact factor: 3.164

3.  Synthesis and evaluation of novel peripherally restricted kappa-opioid receptor agonists.

Authors:  Virendra Kumar; Deqi Guo; Joel A Cassel; Jeffrey D Daubert; Robert N Dehaven; Diane L Dehaven-Hudkins; Erin K Gauntner; Susan L Gottshall; Susan L Greiner; Michael Koblish; Patrick J Little; Erik Mansson; Alan L Maycock
Journal:  Bioorg Med Chem Lett       Date:  2005-02-15       Impact factor: 2.823

4.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results.

Authors:  Steven L Dixon; Alexander M Smondyrev; Eric H Knoll; Shashidhar N Rao; David E Shaw; Richard A Friesner
Journal:  J Comput Aided Mol Des       Date:  2006-11-24       Impact factor: 3.686

5.  A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonist.

Authors:  Nidhi Singh; Gwénaël Chevé; David M Ferguson; Christopher R McCurdy
Journal:  J Comput Aided Mol Des       Date:  2006-09-29       Impact factor: 3.686

Review 6.  International Union of Pharmacology. XII. Classification of opioid receptors.

Authors:  B N Dhawan; F Cesselin; R Raghubir; T Reisine; P B Bradley; P S Portoghese; M Hamon
Journal:  Pharmacol Rev       Date:  1996-12       Impact factor: 25.468

7.  Benzeneacetamide amines: structurally novel non-m mu opioids.

Authors:  J Szmuszkovicz; P F Von Voigtlander
Journal:  J Med Chem       Date:  1982-10       Impact factor: 7.446

8.  A genetic algorithm for flexible molecular overlay and pharmacophore elucidation.

Authors:  G Jones; P Willett; R C Glen
Journal:  J Comput Aided Mol Des       Date:  1995-12       Impact factor: 3.686

9.  2-(3,4-Dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted- ethyl]-acetamides: the use of conformational analysis in the development of a novel series of potent opioid kappa agonists.

Authors:  G F Costello; R James; J S Shaw; A M Slater; N C Stutchbury
Journal:  J Med Chem       Date:  1991-01       Impact factor: 7.446

10.  Chemical function based pharmacophore generation of endothelin-A selective receptor antagonists.

Authors:  Oliver F Funk; Viktor Kettmann; Jan Drimal; Thierry Langer
Journal:  J Med Chem       Date:  2004-05-20       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.